Study the efficacy of risperidone in the treatment of persistent psychosis induced by methamphetamine
Phase 2
Recruiting
- Conditions
- Amphtamine induced psychotic disorder.Mental and behavioural disorders due to use of other stimulants, including caffeine
- Registration Number
- IRCT20130812014333N101
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
The presence of psychosis due to methamphetamine consumption despite discontinuation of methamphetamine for one month
No history of previous psychiatric disorders such as schizophrenia and .....
No medical diseases that have psychosis symptoms such as brain tumors and ...
Exclusion Criteria
No persistent psychosis associated with methamphetamine abuse.
The presence of recent cardiovascular disease based on the patient's history or cardiologist's opinion
Sensitivity or side effects during treatment with risperidone. History or presence of primary psychosis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of psychotic symptoms. Timepoint: At the beginning of the study, the second week and at the end of the study (4 weeks after the start of the study). Method of measurement: Based on the Positive and Negative Symptoms Scale (PANSS).
- Secondary Outcome Measures
Name Time Method